Doctor of Medicine, School of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun, China.
Doctor of Medicine, School of Basic Medicine, Changchun University of Chinese Medicine, Changchun, China.
Medicine (Baltimore). 2022 Apr 22;101(16):e29153. doi: 10.1097/MD.0000000000029153.
In-stent restenosis (ISR) caused by vascular remodeling after percutaneous coronary intervention limits the long-term efficacy of this method. Salvianolate injection is now widely used in the clinical treatment of ISR. However, there is no systematic review or meta-analysis to evaluate the effects of Salvianolate injection on ISR.
We will search articles in 8 electronic databases, including the Cochrane Central Register of Controlled Trials, PubMed, Embase, the Web of Science, China National Knowledge Infrastructure, the Chinese Biomedical Literature Database, Wanfang Database, and the Chinese Scientific Journal Database for randomized controlled trials of ISR treated by Salvianolate injection from their inception to February 27, 2022. The primary outcome measure will be the restenosis rate. The data meeting the inclusion criteria were analyzed by RevMan V.5.4 software. Two authors evaluated the study using the Cochrane collaborative risk bias tool. We will use a scoring method to assess the overall evidence supporting the main results.
This study will analyze the clinical effectiveness of Salvianolate injection in the treatment of ISR.
The findings of this systematic review will provide evidence to evaluate the effectiveness of Salvianolate injection for the treatment of ISR.
INPLASY202220117.
经皮冠状动脉介入治疗后血管重构引起的支架内再狭窄(ISR)限制了该方法的长期疗效。丹参多酚酸盐注射液目前广泛应用于 ISR 的临床治疗。然而,目前尚无系统评价或荟萃分析来评估丹参多酚酸盐注射液对 ISR 的疗效。
我们将从建库至 2022 年 2 月 27 日,在 8 个电子数据库中检索关于丹参多酚酸盐注射液治疗 ISR 的随机对照试验,包括 Cochrane 中央对照试验注册库、PubMed、Embase、Web of Science、中国知网、中国生物医学文献数据库、万方数据库和中国科学引文数据库。主要结局指标为再狭窄率。符合纳入标准的数据采用 RevMan V.5.4 软件进行分析。两位作者使用 Cochrane 协作偏倚风险工具评估研究。我们将采用评分法评估支持主要结果的总体证据。
本研究将分析丹参多酚酸盐注射液治疗 ISR 的临床疗效。
本系统评价的结果将为评估丹参多酚酸盐注射液治疗 ISR 的有效性提供证据。
INPLASY 注册号:INPLASY202220117。